Pfizer Balance Sheet Analysis From 2010 to 2024

PFE Stock

USD 25.39 0.03 0.12%

Most indicators from Pfizer's financial ratios are interrelated and interconnected. However, analyzing financial ratios indicators one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of financial ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Pfizer Valuation and Pfizer Correlation analysis.

At present, Pfizer's Enterprise Value is projected to increase significantly based on the last few years of reporting.

Most indicators from Pfizer's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Pfizer Valuation and Pfizer Correlation analysis.

At present, Pfizer's Enterprise Value is projected to increase significantly based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Gross Profit	50.5B	66.0B	29.3B	30.4B
Total Revenue	81.3B	100.3B	58.5B	39.5B

Gross Profit Total Revenue

Pfizer fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant Equipment	Accounts Payable	Common Stock Total Equity
Total Assets		0.85	0.7	0.88	0.77	0.84	0.82	0.77	0.25	0.97	0.56	0.44	0.54	0.58	0.93	0.73	0.6	-0.12	0.98	0.71	0.64	0.35	0.87	0.84	0.87	0.91
Short Long Term Debt Total	0.85		0.6	0.85	0.4	0.6	0.99	0.75	0.07	0.93	0.35	0.0	0.18	0.27	0.84	0.53	0.8	-0.35	0.9	0.7	0.21	0.51	0.85	0.6	0.8	0.7
Other Current Liab	0.7	0.6		0.87	0.52	0.58	0.61	0.79	-0.07	0.7	0.84	0.16	0.34	0.07	0.44	0.59	0.72	-0.44	0.64	0.92	0.36	-0.12	0.49	0.58	0.89	0.54
Total Current Liabilities	0.88	0.85	0.87		0.59	0.73	0.85	0.9	-0.01	0.91	0.68	0.12	0.37	0.2	0.71	0.73	0.74	-0.47	0.88	0.84	0.37	0.35	0.72	0.73	0.96	0.78
Total Stockholder Equity	0.77	0.4	0.52	0.59		0.92	0.37	0.55	0.3	0.66	0.67	0.64	0.72	0.59	0.66	0.87	0.2	0.08	0.68	0.46	0.86	0.21	0.55	0.92	0.62	0.81
Property Plant And Equipment Net	0.84	0.6	0.58	0.73	0.92		0.58	0.63	0.24	0.79	0.62	0.41	0.72	0.54	0.76	0.95	0.31	-0.05	0.8	0.57	0.71	0.37	0.67	1.0	0.72	0.87
Net Debt	0.82	0.99	0.61	0.85	0.37	0.58		0.79	-0.06	0.91	0.36	-0.07	0.11	0.19	0.79	0.52	0.83	-0.44	0.88	0.71	0.15	0.51	0.81	0.58	0.8	0.68
Retained Earnings	0.77	0.75	0.79	0.9	0.55	0.63	0.79		-0.24	0.82	0.68	0.05	0.13	-0.02	0.6	0.7	0.79	-0.71	0.76	0.84	0.28	0.28	0.54	0.63	0.92	0.78
Cash	0.25	0.07	-0.07	-0.01	0.3	0.24	-0.06	-0.24		0.14	-0.05	0.5	0.58	0.65	0.35	0.09	-0.27	0.65	0.23	-0.1	0.47	0.06	0.26	0.24	-0.02	0.16
Non Current Assets Total	0.97	0.93	0.7	0.91	0.66	0.79	0.91	0.82	0.14		0.56	0.22	0.41	0.44	0.91	0.7	0.71	-0.26	0.98	0.76	0.44	0.42	0.9	0.79	0.9	0.86
Non Currrent Assets Other	0.56	0.35	0.84	0.68	0.67	0.62	0.36	0.68	-0.05	0.56		0.17	0.39	0.04	0.28	0.64	0.52	-0.34	0.46	0.76	0.37	-0.12	0.36	0.62	0.76	0.45
Cash And Short Term Investments	0.44	0.0	0.16	0.12	0.64	0.41	-0.07	0.05	0.5	0.22	0.17		0.55	0.72	0.44	0.29	-0.17	0.48	0.35	0.0	0.91	-0.13	0.21	0.41	0.13	0.48
Net Receivables	0.54	0.18	0.34	0.37	0.72	0.72	0.11	0.13	0.58	0.41	0.39	0.55		0.76	0.46	0.61	-0.22	0.46	0.46	0.24	0.73	0.05	0.41	0.72	0.35	0.52
Common Stock Shares Outstanding	0.58	0.27	0.07	0.2	0.59	0.54	0.19	-0.02	0.65	0.44	0.04	0.72	0.76		0.67	0.31	-0.16	0.7	0.53	0.02	0.76	0.12	0.58	0.54	0.18	0.52
Non Current Liabilities Total	0.93	0.84	0.44	0.71	0.66	0.76	0.79	0.6	0.35	0.91	0.28	0.44	0.46	0.67		0.61	0.49	0.03	0.96	0.51	0.6	0.47	0.89	0.76	0.68	0.87
Inventory	0.73	0.53	0.59	0.73	0.87	0.95	0.52	0.7	0.09	0.7	0.64	0.29	0.61	0.31	0.61		0.31	-0.26	0.7	0.58	0.61	0.39	0.49	0.95	0.7	0.83
Other Current Assets	0.6	0.8	0.72	0.74	0.2	0.31	0.83	0.79	-0.27	0.71	0.52	-0.17	-0.22	-0.16	0.49	0.31		-0.64	0.62	0.82	-0.03	0.12	0.56	0.31	0.76	0.41
Other Stockholder Equity	-0.12	-0.35	-0.44	-0.47	0.08	-0.05	-0.44	-0.71	0.65	-0.26	-0.34	0.48	0.46	0.7	0.03	-0.26	-0.64		-0.17	-0.53	0.34	-0.17	0.05	-0.05	-0.48	-0.21
Total Liab	0.98	0.9	0.64	0.88	0.68	0.8	0.88	0.76	0.23	0.98	0.46	0.35	0.46	0.53	0.96	0.7	0.62	-0.17		0.68	0.55	0.46	0.89	0.8	0.84	0.9
Property Plant And Equipment Gross	0.71	0.7	0.92	0.84	0.46	0.57	0.71	0.84	-0.1	0.76	0.76	0.0	0.24	0.02	0.51	0.58	0.82	-0.53	0.68		0.22	-0.1	0.53	0.57	0.89	0.57
Total Current Assets	0.64	0.21	0.36	0.37	0.86	0.71	0.15	0.28	0.47	0.44	0.37	0.91	0.73	0.76	0.6	0.61	-0.03	0.34	0.55	0.22		0.03	0.38	0.71	0.38	0.7
Short Term Debt	0.35	0.51	-0.12	0.35	0.21	0.37	0.51	0.28	0.06	0.42	-0.12	-0.13	0.05	0.12	0.47	0.39	0.12	-0.17	0.46	-0.1	0.03		0.43	0.37	0.2	0.43
Intangible Assets	0.87	0.85	0.49	0.72	0.55	0.67	0.81	0.54	0.26	0.9	0.36	0.21	0.41	0.58	0.89	0.49	0.56	0.05	0.89	0.53	0.38	0.43		0.67	0.73	0.68
Property Plant Equipment	0.84	0.6	0.58	0.73	0.92	1.0	0.58	0.63	0.24	0.79	0.62	0.41	0.72	0.54	0.76	0.95	0.31	-0.05	0.8	0.57	0.71	0.37	0.67		0.72	0.87
Accounts Payable	0.87	0.8	0.89	0.96	0.62	0.72	0.8	0.92	-0.02	0.9	0.76	0.13	0.35	0.18	0.68	0.7	0.76	-0.48	0.84	0.89	0.38	0.2	0.73	0.72		0.76
Common Stock Total Equity	0.91	0.7	0.54	0.78	0.81	0.87	0.68	0.78	0.16	0.86	0.45	0.48	0.52	0.52	0.87	0.83	0.41	-0.21	0.9	0.57	0.7	0.43	0.68	0.87	0.76

Click cells to compare fundamentals

Pfizer Account Relationship Matchups

Pfizer fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	167.5B	154.2B	181.5B	197.2B	226.5B	237.8B
Net Debt	50.8B	36.5B	35.1B	34.5B	72.2B	75.8B
Retained Earnings	97.7B	96.8B	103.4B	125.7B	118.4B	124.3B
Cash	1.3B	1.8B	1.9B	416M	2.9B	2.0B
Net Receivables	12.1B	11.2B	15.7B	14.5B	11.2B	8.7B
Inventory	8.3B	8.0B	9.1B	9.0B	10.2B	5.2B
Other Current Assets	2.6B	3.4B	3.8B	5.0B	9.3B	9.7B
Total Liab	104.0B	90.8B	104.0B	101.3B	137.2B	144.1B
Total Current Assets	32.8B	35.1B	59.7B	51.3B	43.3B	32.2B
Short Term Debt	16.2B	2.7B	2.2B	2.9B	10.9B	5.7B
Intangible Assets	35.4B	28.5B	25.1B	43.4B	64.9B	68.1B
Accounts Payable	4.2B	4.3B	5.6B	6.8B	6.7B	7.0B
Capital Stock	468M	470M	473M	476M	478M	474.0M
Common Stock	468M	470M	473M	476M	478M	474.0M
Other Liab	29.7B	26.6B	22.6B	23.3B	26.9B	22.1B
Other Assets	4.2B	4.3B	5.6B	6.8B	6.7B	5.0B
Long Term Debt	36.0B	37.1B	36.2B	32.9B	60.5B	63.5B
Good Will	58.7B	49.6B	49.2B	51.4B	67.8B	40.7B
Treasury Stock	(110.8B)	(111.0B)	(111.4B)	(114.0B)	(114.5B)	(108.8B)
Net Tangible Assets	(30.9B)	63.2B	77.2B	95.7B	89.0B	93.5B

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:

How To Invest In Pfizer

Details

Is Pfizer Stock a good investment?

Details

What is Pfizer's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Pfizer Valuation and Pfizer Correlation analysis.

Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.

	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges

Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.76)

Dividend Share

1.64

Earnings Share

0.37

Revenue Per Share

10.366

Quarterly Revenue Growth

(0.41)

The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pfizer Balance Sheet Analysis From 2010 to 2024

Pfizer fundamental ratios Correlations

Pfizer Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pfizer fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Pfizer Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Net Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.98	Total Assets
Total Liab	+ 0.98	Non Current Assets Total
Non Current Assets Total	+ 0.97	Total Assets
Accounts Payable	+ 0.96	Total Current Liabilities

Other Stockholder Equity	- 0.71	Retained Earnings
Other Stockholder Equity	- 0.64	Other Current Assets
Property Plant And Equipment Gross	- 0.53	Other Stockholder Equity
Accounts Payable	- 0.48	Other Stockholder Equity
Other Stockholder Equity	- 0.47	Total Current Liabilities
Other Stockholder Equity	- 0.44	Net Debt